Heartflow, Inc. Common Stock (HTFL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 87 | 126 | 176 | 212 | 249 |
| Operating profit | $m | -64 | -73 | ||||||
| Net profit | $m | - | - | - | -96 | -96 | -117 | -118 | -36 |
| EPS reported | $ | -1.37 | -1.42 | ||||||
| Operating cashflow per share | $ | -0.63 | -0.60 | ||||||
| Capex per share | $ | 0.06 | 0.08 | ||||||
| FCF per share | $ | -0.69 | -0.68 | ||||||
| Free cash flow | $m | -59 | -59 | ||||||
| Net debt | $m | -177 | -163 | ||||||
| Book value equity | $m | 301 | 280 | ||||||
| Book value per share | $ | 3.53 | 3.24 | ||||||
| Number of shares | m | 85.28 | 86.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 8.27 | 8.89 | ||||||
| P/S LTM | x | 14.12 | 11.72 | ||||||
| P/FCF LTM | x | -42.10 | -42.01 | ||||||
| EV/EBITDA LTM | x | -26.45 | -22.76 | ||||||
| EV/Sales LTM | x | 13.99 | 17.08 | ||||||
| Earnings Yield LTM | % | -4.70% | -3.26% | ||||||
| FCF Yield | % | -2.38% | -2.38% | ||||||
| Quality | |||||||||
| ROE | % | -38.85% | -42.25% | ||||||
| ROIC | % | -19.82% | -23.67% | ||||||
| Operating margin | % | -36.39% | -34.31% | ||||||
| Gross margin | % | +76.80% | +80.08% | ||||||
| FCF/Sales | % | -33.54% | -27.91% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +39.92% | +68.57% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.68 | -2.18 | ||||||
| Net Debt/EBITDA | x | 0.24 | 0.07 | ||||||
| EBIT/Net interest | x | -4.22 | -21.02 | ||||||
| Net debt/market cap | % | 0.00% | +0.75% | ||||||
| Net debt/Equity | x | -0.59 | -0.58 | ||||||
| Gross debt/equity | x | 0.07 | 0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Heartflow, Inc. Common Stock (HTFL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free